FDA adds vision-loss warning to GLP-1 drugs
Statements (5)
- Bearish
FDA orders new vision loss warning for Ozempic and other GLP-1s
- Neutral
FDA adds rare vision-loss warning to GLP-1 drugs
- Neutral
The FDA ordered GLP-1 medication makers to add a warning about increased risk of vision loss on their drug labels.
- Neutral
FDA requires GLP-1 drugmakers to update product labels to warn of a rare eye condition that could lead to blindness.
- Neutral
FDA adds warning label to weight-loss drugs for eye condition